U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C10H21NO7
Molecular Weight 267.2762
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of VOGLIBOSE

SMILES

OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O

InChI

InChIKey=FZNCGRZWXLXZSZ-CIQUZCHMSA-N
InChI=1S/C10H21NO7/c12-2-5(3-13)11-6-1-10(18,4-14)9(17)8(16)7(6)15/h5-9,11-18H,1-4H2/t6-,7-,8+,9-,10-/m0/s1

HIDE SMILES / InChI
Molecular Formula C10H21NO7
Molecular Weight 267.2762
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 5 / 5
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Voglibose is an alpha glucosidase inhibitor, which was initially marketed in Japan as an improving agent for postprandial hyperglycemia in diabetes mellitus. Later on the drug was approved for the prevention of type 2 diabetes. The drug is available in Asia under the name Basen.

Originator

Approval Year

Unknown
149124
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8504
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
BASEN

Approved Use

Improvement of postprandial hyperglycemia in diabetes mellitus

Launch Date

1994
Preventing
Approved
8583
BASEN

Approved Use

Prevention of the onset of type 2 diabetes in patients with impaired glucose tolerance.

Launch Date

2009
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
20.7 ng/mL
OTHER GOV'T
https://www.info.pmda.go.jp/go/interview/2/400061_3969004F1020_2_001_1F.pdf#page=40
80 mg single, oral
dose: 80 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VOGLIBOSE blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
168 ng × h/mL
OTHER GOV'T
https://www.info.pmda.go.jp/go/interview/2/400061_3969004F1020_2_001_1F.pdf#page=40
80 mg single, oral
dose: 80 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VOGLIBOSE blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
5.33 h
OTHER GOV'T
https://www.info.pmda.go.jp/go/interview/2/400061_3969004F1020_2_001_1F.pdf#page=40
80 mg single, oral
dose: 80 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VOGLIBOSE blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
93%
OTHER GOV'T
https://www.info.pmda.go.jp/go/interview/2/400061_3969004F1020_2_001_1F.pdf#page=47
VOGLIBOSE serum
Homo sapiens
Doses

Doses

DosePopulationAdverse events​
5 mg 3 times / day multiple, oral
Highest studied dose
Dose: 5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 5 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/8536820/
healthy, ADULT
Health Status: healthy
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Sources:
https://pubmed.ncbi.nlm.nih.gov/8536820/
Sources:
https://pubmed.ncbi.nlm.nih.gov/8536820/
0.2 mg 3 times / day multiple, oral
Recommended
Dose: 0.2 mg, 3 times / day
Route: oral
Route: multiple
Dose: 0.2 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/20590736/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Sources:
https://pubmed.ncbi.nlm.nih.gov/20590736/
Disc. AE: Gastrointestinal disturbance...
AEs leading to
discontinuation/dose reduction:
Gastrointestinal disturbance (grade 1-2, 1.28%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/20590736/
0.2 mg 3 times / day multiple, oral
Recommended
Dose: 0.2 mg, 3 times / day
Route: oral
Route: multiple
Dose: 0.2 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21806314/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Sources:
https://pubmed.ncbi.nlm.nih.gov/21806314/
Disc. AE: ALT increased, AST increased...
AEs leading to
discontinuation/dose reduction:
ALT increased (1.2%)
AST increased (1.2%)
Gamma-glutamyltransferase increased (1.2%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/21806314/
AEs

AEs

AESignificanceDosePopulation
Gastrointestinal disturbance grade 1-2, 1.28%
Disc. AE
0.2 mg 3 times / day multiple, oral
Recommended
Dose: 0.2 mg, 3 times / day
Route: oral
Route: multiple
Dose: 0.2 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/20590736/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Sources:
https://pubmed.ncbi.nlm.nih.gov/20590736/
ALT increased 1.2%
Disc. AE
0.2 mg 3 times / day multiple, oral
Recommended
Dose: 0.2 mg, 3 times / day
Route: oral
Route: multiple
Dose: 0.2 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21806314/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Sources:
https://pubmed.ncbi.nlm.nih.gov/21806314/
AST increased 1.2%
Disc. AE
0.2 mg 3 times / day multiple, oral
Recommended
Dose: 0.2 mg, 3 times / day
Route: oral
Route: multiple
Dose: 0.2 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21806314/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Sources:
https://pubmed.ncbi.nlm.nih.gov/21806314/
Gamma-glutamyltransferase increased 1.2%
Disc. AE
0.2 mg 3 times / day multiple, oral
Recommended
Dose: 0.2 mg, 3 times / day
Route: oral
Route: multiple
Dose: 0.2 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21806314/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Sources:
https://pubmed.ncbi.nlm.nih.gov/21806314/
PubMed

PubMed

TitleDatePubMed
Voglibose for prevention of type 2 diabetes mellitus.
2009-08-08
A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease.
2009-07-20
Suppressive response of confections containing the extractive from leaves of Morus Alba on postprandial blood glucose and insulin in healthy human subjects.
2009-07-14
Effects of changeover from voglibose to acarbose on postprandial triglycerides in type 2 diabetes mellitus patients.
2009-06
Voglibose for prevention of type 2 diabetes mellitus.
2009-05-09
Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance.
2009-05-09
Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats.
2009-05-01
Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice.
2009-05
Alpha-glucosidase inhibition assay in an enzyme-immobilized amino-microplate.
2009-04
Development and validation of LC methods with visible detection using pre-column derivatization and mass detection for the assay of voglibose.
2009-03-15
Effects of the combination of dipeptidyl peptidase-IV inhibitor ASP8497 and antidiabetic drugs in streptozotocin-nicotinamide-induced mildly diabetic mice.
2009-03-01
[Simultaneous determination of four highly polar anti-diabetic drugs in Chinese traditional patent medicines using high performance liquid chromatography].
2009-03
Novel LMNA gene mutation in a patient with Atypical Werner's Syndrome.
2009-03
Topics in type 2 diabetes and insulin resistance.
2009-02
Comparison of pre- versus post-meal administration of voglibose in men with or without impaired glucose tolerance.
2009-02
Genetically engineered production of 1,1'-bis-valienamine and validienamycin in Streptomyces hygroscopicus and their conversion to valienamine.
2009-01
Design and synthesis of 5a-carbaglycopyranosylamime glycosidase inhibitors.
2009
Involvement of hyperglycemia in deposition of aggregated protein in glomeruli of diabetic mice.
2008-12-28
Switch to oral hypoglycemic agent therapy from insulin injection in patients with type 2 diabetes.
2008-12
Effects of antidiabetic drugs on glucose tolerance in streptozotocin-nicotinamide-induced mildly diabetic and streptozotocin-induced severely diabetic mice.
2008-12
Hypoglycaemic effects of antidiabetic drugs in streptozotocin-nicotinamide-induced mildly diabetic and streptozotocin-induced severely diabetic rats.
2008-12
Improvement in medication compliance and glycemic control with voglibose oral disintegrating tablet.
2008-11
Pneumatosis cystoides intestinalis following alpha-glucosidase inhibitor treatment: a case report and review of the literature.
2008-10-21
Intramolecular direct aldol reactions of sugar diketones: syntheses of valiolamine and validoxylamine G.
2008-09-18
Alpha glucosidase inhibitor voglibose can prevent pioglitazone-induced body weight gain in Type 2 diabetic patients.
2008-08
Acute progression of severe insulin edema accompanied by pericardial and pleural effusion in a patient with type 2 diabetes.
2008-08
Alpha-glucosidase-like activity detected in a siboglinid polychaete, Oligobrachia mashikoi.
2008-04
Alpha-glucosidase inhibitors in the early treatment of type 2 diabetes.
2008
Peroxisome proliferator-activated receptors in diabetic nephropathy.
2008
Protective Actions of PPAR-gamma Activation in Renal Endothelium.
2008
Change in long-spacing collagen in Descemet's membrane of diabetic Goto-Kakizaki rats and its suppression by antidiabetic agents.
2008
PPAR Agonists and Cardiovascular Disease in Diabetes.
2008
Combination therapy of pioglitazone with voglibose improves glycemic control safely and rapidly in Japanese type 2-diabetic patients on hemodialysis.
2007-11
[Adverse effects of alpha-glucosidase inhibitors].
2007-10-28
Administration of miglitol until 30 min after the start of a meal is effective in type 2 diabetic patients.
2007-10
Comparison of the effects of pioglitazone and voglibose on circulating total and high-molecular-weight adiponectin, and on two fibrinolysis inhibitors, in patients with Type 2 diabetes.
2007-09
Thioglycosides as inhibitors of hSGLT1 and hSGLT2: potential therapeutic agents for the control of hyperglycemia in diabetes.
2007-05-05
Indian herbs and herbal drugs used for the treatment of diabetes.
2007-05
Comparison of efficacies of a dipeptidyl peptidase IV inhibitor and alpha-glucosidase inhibitors in oral carbohydrate and meal tolerance tests and the effects of their combination in mice.
2007-05
Pioglitazone produces rapid and persistent reduction of vascular inflammation in patients with hypertension and type 2 diabetes mellitus who are receiving angiotensin II receptor blockers.
2007-04
A review of nateglinide in the management of patients with type 2 diabetes.
2007
Determination of miglitol in human plasma by liquid chromatography/tandem mass spectrometry.
2007
Abnormal glucose tolerance contributes to the progression of chronic heart failure in patients with dilated cardiomyopathy.
2006-10
Quantitative determination of voglibose in pharmaceutical tablets using high-performance liquid chromatography-fluorescence detection with post-column derivatization and mass spectrometric detection.
2006-09-26
An alpha-glucosidase inhibitor, voglibose, reduces oxidative stress markers and soluble intercellular adhesion molecule 1 in obese type 2 diabetic patients.
2006-06
Voglibose inhibits postprandial hypotension in neurologic disorders and elderly people.
2006-05-09
Control of plasma glucose with alpha-glucosidase inhibitor attenuates oxidative stress and slows the progression of heart failure in mice.
2006-04-01
Efficacy and adverse effects of nateglinide in early type 2 diabetes. Comparison with voglibose in a cross-over study.
2006-04
A rare case of adult-onset nesidioblastosis treated successfully with diazoxide.
2006-02
Synthesis and glycosidase inhibitory activity of new hexa-substituted C8-glycomimetics.
2005-10-07
Patents

Patents

JP2000103731A
7
JP2000344660A
1
JP2000504736A
1
JP2000505784A
1
JP2000507197A
1
JP2000515113A
1
JP2001002567A
1
JP2001509795A
2
JP2001515084A
1
JP2001523704A
2
JP2002500643A
10
JP2002520418A
1
JP2002537393A
1
JP2002542232A
1
JP2002542344A
1
JP2003500078A
1
JP2003500474A
1
JP2003500475A
1
JP2003505358A
1
JP2003506426A
1
JP2003509401A
1
JP2003510350A
1
JP2003511451A
1
JP2003517303A
1
JP2003517466A
1
JP2003522758A
4
JP2004315496A
25
JP2004502792A
1
JP2004525900A
3
JP2004527465A
1
JP2004536830A
1
JP2005502735A
1
JP2005511566A
1
JP2005511570A
1
JP2005511694A
1
JP2005512806A
1
JP2005516018A
1
JP2005522496A
1
JP2005522510A
1
JP2005522511A
1
JP2005526795A
3
JP2005535584A
1
JP2005535649A
1
JP2005538073A
1
JP2005538968A
1
JP2006008548A
1
JP2006016388A
1
JP2006131564A
1
JP2006501063A
1
JP2006502119A
1
JP2006503013A
1

Sample Use Guides

In Vivo Use Guide
Tablets are orally administered in a single dose of 0.2 mg as voglibose, three times a day, just before each meal.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Wed Apr 02 09:37:05 GMT 2025
Edited
by admin
on Wed Apr 02 09:37:05 GMT 2025
Record UNII
S77P977AG8
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
VOGLIBOSE
INN   MART.   MI   USAN   WHO-DD  
USAN   INN  
Official Name English
BASEN
Preferred Name English
VOGLIBOSE [USAN]
Common Name English
Voglibose [WHO-DD]
Common Name English
D-EPI-INOSITOL, 3,4-DIDEOXY-4-((2-HYDROXY-1-(HYDROXYMETHYL)ETHYL)AMINO)-2-C-(HYDROXYMETHYL)-
Systematic Name English
VOGLIBOSE [JAN]
Common Name English
AO-128
Code English
A-71100
Code English
3,4-DIDEOXY-4-((2-HYDROXY-1-(HYDROXYMETHYL)ETHYL)AMINO)-2-C-(HYDROXYMETHYL)-D-EPI-INOSITOL
Systematic Name English
N-(1,3-DIHYDROXY-2-PROPYL)VALIOLAMINE
Common Name English
VOGLIBOSE [MI]
Common Name English
voglibose [INN]
Common Name English
VOGLIBOSE [MART.]
Common Name English
Classification Tree Code System Code
WHO-ATC A10BF03
Created by admin on Wed Apr 02 09:37:05 GMT 2025 , Edited by admin on Wed Apr 02 09:37:05 GMT 2025
NCI_THESAURUS C2846
Created by admin on Wed Apr 02 09:37:05 GMT 2025 , Edited by admin on Wed Apr 02 09:37:05 GMT 2025
WHO-VATC QA10BF03
Created by admin on Wed Apr 02 09:37:05 GMT 2025 , Edited by admin on Wed Apr 02 09:37:05 GMT 2025
NCI_THESAURUS C29711
Created by admin on Wed Apr 02 09:37:05 GMT 2025 , Edited by admin on Wed Apr 02 09:37:05 GMT 2025
Code System Code Type Description
SMS_ID
100000079326
Created by admin on Wed Apr 02 09:37:05 GMT 2025 , Edited by admin on Wed Apr 02 09:37:05 GMT 2025
PRIMARY
DRUG CENTRAL
2845
Created by admin on Wed Apr 02 09:37:05 GMT 2025 , Edited by admin on Wed Apr 02 09:37:05 GMT 2025
PRIMARY
CAS
83480-29-9
Created by admin on Wed Apr 02 09:37:05 GMT 2025 , Edited by admin on Wed Apr 02 09:37:05 GMT 2025
PRIMARY
ChEMBL
CHEMBL476960
Created by admin on Wed Apr 02 09:37:05 GMT 2025 , Edited by admin on Wed Apr 02 09:37:05 GMT 2025
PRIMARY
EVMPD
SUB00085MIG
Created by admin on Wed Apr 02 09:37:05 GMT 2025 , Edited by admin on Wed Apr 02 09:37:05 GMT 2025
PRIMARY
DRUG BANK
DB04878
Created by admin on Wed Apr 02 09:37:05 GMT 2025 , Edited by admin on Wed Apr 02 09:37:05 GMT 2025
PRIMARY
MESH
C102817
Created by admin on Wed Apr 02 09:37:05 GMT 2025 , Edited by admin on Wed Apr 02 09:37:05 GMT 2025
PRIMARY
CHEBI
22695
Created by admin on Wed Apr 02 09:37:05 GMT 2025 , Edited by admin on Wed Apr 02 09:37:05 GMT 2025
PRIMARY
INN
6797
Created by admin on Wed Apr 02 09:37:05 GMT 2025 , Edited by admin on Wed Apr 02 09:37:05 GMT 2025
PRIMARY
FDA UNII
S77P977AG8
Created by admin on Wed Apr 02 09:37:05 GMT 2025 , Edited by admin on Wed Apr 02 09:37:05 GMT 2025
PRIMARY
WIKIPEDIA
Voglibose
Created by admin on Wed Apr 02 09:37:05 GMT 2025 , Edited by admin on Wed Apr 02 09:37:05 GMT 2025
PRIMARY
EPA CompTox
DTXSID2021442
Created by admin on Wed Apr 02 09:37:05 GMT 2025 , Edited by admin on Wed Apr 02 09:37:05 GMT 2025
PRIMARY
MERCK INDEX
m11496
Created by admin on Wed Apr 02 09:37:05 GMT 2025 , Edited by admin on Wed Apr 02 09:37:05 GMT 2025
PRIMARY Merck Index
PUBCHEM
444020
Created by admin on Wed Apr 02 09:37:05 GMT 2025 , Edited by admin on Wed Apr 02 09:37:05 GMT 2025
PRIMARY
USAN
KK-13
Created by admin on Wed Apr 02 09:37:05 GMT 2025 , Edited by admin on Wed Apr 02 09:37:05 GMT 2025
PRIMARY
NCI_THESAURUS
C95221
Created by admin on Wed Apr 02 09:37:05 GMT 2025 , Edited by admin on Wed Apr 02 09:37:05 GMT 2025
PRIMARY
Related Record Type Details
Structure of VOGLIBOSE
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966